Neuphoria Therapeutics (NEUP) Assets Average (2021 - 2025)
Historic Assets Average for Neuphoria Therapeutics (NEUP) over the last 5 years, with Q4 2025 value amounting to $32.0 million.
- Neuphoria Therapeutics' Assets Average rose 5563.23% to $32.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $32.0 million, marking a year-over-year increase of 5563.23%. This contributed to the annual value of $37.9 million for FY2023, which is N/A changed from last year.
- Neuphoria Therapeutics' Assets Average amounted to $32.0 million in Q4 2025, which was up 5563.23% from $28.0 million recorded in Q3 2025.
- In the past 5 years, Neuphoria Therapeutics' Assets Average registered a high of $48.1 million during Q2 2022, and its lowest value of $20.5 million during Q4 2024.
- Its 5-year average for Assets Average is $30.1 million, with a median of $28.0 million in 2025.
- In the last 5 years, Neuphoria Therapeutics' Assets Average plummeted by 2149.75% in 2023 and then soared by 5563.23% in 2025.
- Quarter analysis of 5 years shows Neuphoria Therapeutics' Assets Average stood at $25.1 million in 2021, then skyrocketed by 91.87% to $48.1 million in 2022, then dropped by 21.5% to $37.8 million in 2023, then crashed by 45.6% to $20.5 million in 2024, then surged by 55.63% to $32.0 million in 2025.
- Its Assets Average stands at $32.0 million for Q4 2025, versus $28.0 million for Q3 2025 and $29.7 million for Q2 2025.